Enanta Pharma (ENTA) Tops Q1 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Enanta Pharma (ENTA) Tops Q1 EPS by 23c

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015

February 8, 2016 4:02 PM EST

Conference Call and Webcast Today at 4:30 p.m. ET

Royalty revenue for paritaprevir containing regimens was $17.9 million $30 million milestone payment received from AbbVie for reimbursement approval in Japan for VIEKIRAX® Cash and marketable securities totaled $236.6 million at December 31, 2015

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first... More